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The tumor protein p63/microRNA functional network appears to play a decisive role in chemoresis-
tance of human epithelial cancers. The cisplatin- and phosphorylated-DNp63a-dependent microR-
NAs, whose expression was varied in sensitive and resistant squamous cell carcinoma cells (SCC,
which were derived from larynx and tongue tumors), were shown to modulate the expression of
multiple members of cell cycle arrest, apoptosis and autophagy pathways. The speciﬁc microRNAs
were further shown to modulate the resistant phenotype of SCC cells in vitro, thereby providing
groundwork for novel chemotherapeutic venues for head and neck cancer.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Altered expression of microRNAs has been found in many can-
cers and shown the oncogenic, tumor-suppressive or apoptotic po-
tential of speciﬁc microRNAs [1–3]. Certain microRNAs mediate
the induction of cell death, cell cycle arrest, autophagy and senes-
cence and contribute to epithelial stem cell maturation [4–7]. On
the one hand, microRNAs were recently shown to directly bind
to gene promoter and gene terminus sequences, thereby modulat-
ing speciﬁc gene transcription [8,9]. On the other hand, transcrip-
tional networks that are often deregulated in cancer cells may lead
to altered transcription of speciﬁc microRNA genes [10]. MicroR-
NAs may also have therapeutic applications by which cancer-caus-
ing microRNAs could be modulated to restore the normal cellular
function [11]. The modiﬁed cholesterol-conjugated antisense des-
ignated ‘‘antagomirs’’ effectively inhibit microRNA functions
in vivo [12]. The competitive microRNA inhibitors (‘‘microRNA
sponges’’) were reported to de-repress microRNA targets as
strongly as chemically modiﬁed antisense oligonucleotides [13].We previously observed that the cisplatin treatment dramati-
cally down regulated DNp63a in squamous cell carcinoma (SCC)
cells through an ATM-dependent phosphorylation mechanism
[14]. Phosphorylated (p)-DNp63a protein was show to be critical
for the transcriptional regulation of downstream mRNAs and
microRNAs in SCC cells upon cisplatin exposure [15,16]. Moreover,
we reported that p-DNp63a regulates microRNA expression in cis-
platin-treated SCC cells through both transcriptional and post-tran-
scriptional mechanisms [16]. We further showed that the speciﬁc
microRNAs down regulated (181a–5p, 374a–5p and 519a–3p) or
up regulated (630 and 885–3p) in SCC cells in response to cisplatin
treatment are involved in the broad plethora of cellular processes,
including cell cycle arrest, apoptosis, autophagy and various meta-
bolic and signaling pathways [16–18]. In this report, we continue
our quest to understand the role for the cisplatin- and p-DNp63a-
dependent microRNAs in cell survival and chemoresistance.
2. Materials and methods
2.1. Cells, reagents and antibodies
SCC-11 cell line (expressing wt-TP53, wt-TP63 is ampliﬁed and
DNp63a is overexpressed) was derived from the primary larynx
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(SCC-11) or DNp63a-S385G (SCC-11M, which has an impaired site
for ATM kinase phosphorylation) were generated using knock-in
technology [14]. We also used cisplatin-sensitive SCC-25 cells
and SCC-25CP cells with a spontaneously acquired cisplatin resis-
tance, which were derived from the primary SCC of tongue and ob-
tained from Dr. J.S. Lazo (Department of Pharmacology, University
of Pittsburgh School of Medicine) as a result of the Material Trans-
fer Agreement [19]. Cells were incubated with control medium or
with 10 lg/ml cis-diammine-dichloro-platinum-dichloride (cis-
platin, Sigma, P4394). Total lysates were used for immunoblotting
[18–20] with the antibodies against b-actin (Sigma), ATM (LS-
B491), ATG5 (LS-C69125), NFYA (LS-C9324), CASP2 (clone Y154,
LS-C49531) and CDK2 (LS-B352), all from LifeSpan Biosciences,
CDK1 (E53, ab32030, Abcam), ATG10 (EPR4804, NBP1-95893, No-
vus Biologicals), and CDKN2B (H00001030-A01, Abnova).
2.2. Quantitative (q)-PCR of microRNAs
All reagents and kits were obtained from Applied Biosystems.
microRNAs were isolated using mirVana microRNA kit
(#AM1560) and cDNA was synthesized by the High Capacity cDNA
Reverse Transcription kit (#4374966). A quantitative 2-step qRT-
PCR was performed using the TaqMan MicroRNA Assay Kit
(#4380911) and TaqMan Gene Expression Master Mix, 1-Pack
(#4369016). The individual kits for mature microRNAs: hsa-miR-
485-5p (#4427975S), hsa-miR-194-5p (#4427975S), hsa-miR-98
(#4427975S), hsa-miR-29c-3p (#4427975S), hsa-miR-101-3p
(#4427975S), hsa-miR-22-3p (#4427975S), hsa-miR-34c-3p
(4427975S), hsa-miR-206 (#4427975S), hsa-miR-429
(#4427975S), hsa-miR-339-3p (#4427975S), hsa-miR-203a
(#4427975S), hsa-miR-25-3p (#4427975S), hsa-miR-155-5p
(#4427975S), hsa-miR-148a-3p (#4427975S) and for precursor
hsa-mir-297 (#4427012S). Hsa-miR-382-3p expression kit
(MMIR-0382⁄) was from Quanta BioSciences, Inc. Reaction condi-
tions were 50 C for 2 min, 95 C for 10 min, 40 cycles of 95 C
for 15 s and 60 C for 1 min in 20 ll [16].
2.3. Transfection with microRNA mimics
The following human mirVana microRNA mimics: hsa-miR-
297, hsa-25-3p, hsa-29c-3p, hsa-miR-382-3p, hsa-miR-98-5p, and
hsa-miR-429 were purchased from Applied Biosystems. Cells were
transfected in a 6-well plate with 100 pmol of the mimic or scram-
bled RNA in 500 ll serum-free media with 5 ll of Lipofectamine-
2000 reagent (Invitrogen) for 36 h. Each experiment was per-
formed independently 3 times and in triplicate [17,18].
2.4. Luciferase reporter assay
The 30-UTR luciferase reporter plasmids for ATM (SC221017, Ori-
gene Technologies), CASP2 (S811761), CASP3 (S809759), ATG5
(S813215), ATG10 (S806774), NFYA (S809941), CDK1 (S802386),
CDK2 (S808445), CDKN1C (S804105), and CDKN2B (S813977) all
from SwitchGear Genomics were used. 5  104 cells/well in a 24-
well platewere transfectedwith the empty pLightSwitch_3UTRvec-
tor (S890005) using Fugene HD reagent (Roche). Cells were also
transfected with the selected 30-UTR plasmids, along with 100 ng
of the microRNA mimics. At 36 h, cells were treated with 10 lg/ml
cisplatin orwithout cisplatin for an additional 12 h. The LightSwitch
Luciferase Assay Kit (SwitchGear Genomics) was used to monitor a
luciferase reporter signal at 480 nm using a luminometer [17,18].
2.5. Cell viability assay
cells/well in 96-well plates were incubated in serum-free med-
ium with 5 lg/ml of the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphe-nyl tetrazolium bromide (MTT assay, American Tissue Culture
Collection) in the dark at 37 C for 4 h. Cells were lysed and incu-
bated at 37 C for 2 h and the measurements (A570 nm to A650 nm)
were obtained on a Spectra Max 250 plate reader (Molecular De-
vices). Each assay was repeated three times in triplicate [18].
2.6. Statistical analysis and bioinformatics
Data were expressed as means ± S.D. Differences in variables
between experimental and control groups were assessed by using
the Student t test. Statistically signiﬁcant difference was accepted
at p < 0.05. For prediction of the microRNA-speciﬁc ‘seed’ se-
quences in target 30-UTRs, we used the following databases: micr-
oRNA.org-Targets and Expression (www.microrna.org),
TargetScan: Prediction of microRNA targets, v5.2 (www.target-
scan.org), and miRDB-MicroRNA Target Prediction and Functional
Study Database, v3.0 (www.mirdb.org). All the targets were se-
lected based on mirSVR scores (from 0.1592 to 0.4882), Phast-
Cons scores (0.4785–0.6679), and target prediction scores (from 55
to 91) assigned by the computational target prediction algorithm
[18].
3. Results
3.1. Differential expression of microRNAs in SCC cells upon cisplatin
exposure
We previously showed that the p-DNp63a is critical for the reg-
ulation of downstream microRNA expression in cisplatin-treated
SCC-11 cells through both transcriptional and post-transcriptional
mechanisms [16]. Using the knock-in technology, we generated the
SCC-11 cells (derived from the primary human larynx tumor),
which have been shown to produce wild type DNp63a, and SCC-
11M cells that exclusively express DNp63a-S385G with an altered
ability to be phosphorylated by ATM kinase. Both types of SCC cells
were exposed to control medium or 10 lg/ml cisplatin for 16 h.
By global analysis of microRNA expression [16], we showed that
the cisplatin exposure led to a down regulation of twenty-eight
microRNAs (e.g. miR-519a-3p, miR-181a-5p, miR-374a-5p, miR-98-5p,
miR-29c-3p, miR-34c-3p, miR-101-3p, miR-22-3p, miR-206,
miR-25-3p, miR-155-5p, miR-429, miR-339-3p, and miR-148a-3p)
for 3.44–19.26 fold (Supplementary Table SI) and up regulation
of ﬁfteen microRNAs (e.g. miR-485-5p, miR-382-3p, miR-574-5p,
miR-297, miR-194-3p, miR-885-3p and miR-630) for 3.36–
7.46 fold (Supplementary Table SII) in SCC-11 cells compared
to SCC-11M cells upon cisplatin exposure [16]. We further
observed that cisplatin exposure induced the deregulation of
microRNAs in SCC-11 cells resulting in down regulation of seven
microRNAs (1.71–3.76 fold) and up regulation of seven microR-
NAs (1.84–4.98 fold), as shown in Supplementary Table SIII.
We then tested the speciﬁc microRNA levels in SCC cells derived
from primary human tumor of tongue (SCC-25 and SCC-25CP). The
SCC-25CP cells are known to spontaneously acquire the resistance
to cisplatin treatment, while SCC-25 cells remain sensitive to this
anti-cancer drug [19]. The SCC-25 cells were shown to express a
greater p-DNp63a/non-p-DNp63a ratio than SCC-25CP cells fur-
ther supporting the potential p-DNp63a contribution to a cisplatin
sensitivity of SCC cells [20].
Using qPCR assays, we found a fair correlation between speciﬁc
microRNAs up regulated or down regulated in sensitive cells (SCC-
11 and SCC-25), or resistant cells (SCC-11M and SCC-25CP), as pre-
sented in Supplementary Table SIV. Moreover, the qPCR assays (in
a limited sampling of head and neck SCC biopsies from larynx and
tongue) showed that miR-98-5p and miR-429 were down regu-
lated, while miR-297 andmiR-282-3p were up regulated in tumor
biopsies from patients with a favorable outcome (S – sensitive),
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Fig. 1. Cisplatin affects expression of microRNAs and their protein targets in SCC-11 cells. (A). qPCR analysis of speciﬁc microRNAs in SCC-11 cells compared to SCC-11M cells
exposed to 10 lg/ml cisplatin for 16 h. Up regulated (above the median line) and down regulated (below the median line) microRNAs are indicated. Fold change expressed as
positive and negative values, respectively. MicroRNA levels in SCC-11M cells were designated as 1. (B). MicroRNA/30-UTR luciferase reporter assays for indicated targets in
SCC-11 cells exposed to control medium. Target protein symbols are indicated above the graph, while speciﬁc microRNA mimics are indicated below the graph. As a negative
control, scrambled microRNA mimic control was used. Experiments were run in triplicates (p < 0.05). (C). SCC-11 cells were exposed to control medium (CON) and 10 lg/ml
cisplatin (CIS) for 16 h. Immunoblot analysis with indicated antibodies. Blots were scanned and quantiﬁed by the Image Quant software version 3.3 (Molecular Dynamics).
Values were normalized by b-actin levels and expressed as a fold of a control sample deﬁned as 1. The lines between speciﬁc blots indicate the independent gel runs.
Experiments were run in triplicates (p < 0.05).
2538 E.A. Ratovitski / FEBS Letters 587 (2013) 2536–2541as opposing trend seen in tumor biopsies from patients with an
unfavorable outcome (R – resistant) of combined platinum thera-
pies (Supplementary Table SV). Interestingly, the sensitive SCC tu-
mor biopsies were also shown to express greater p-DNp63a levels
than the resistant SCC tumor biopsies (Supplementary Fig. S1).
3.2. Cisplatin/p-DNp63a-dependent microRNAs modulate numerous
mRNA targets in SCC-11 cells
Our previous studies showed the critical role for miR-181a-5p,
miR-374a-5p, miR-519a-3p, miR-630 and miR-885-3p in various
cellular responses to the cisplatin treatment, including cell cycle
arrest, apoptosis and autophagy [16–18]. Using qPCR analysis, wefurther investigated that phenomenon and found that miR-485-
3p, miR-297, miR-382-3p and miR-194-5p) were up regulated
(5–6 fold), while miR-98-5p, miR-29c-3p, miR-101-3p, miR-
22-3p, miR-34c-3p, miR-206, miR-429, miR-339-3p, miR-203a,
miR-25-3p, miR-155-5p and miR-148a-3p were down regulated
(6.7–15.4  fold), as shown in Fig. 1A.
Using the 30-UTR-mediated luciferase activity assay, we found
that several mRNA 30-UTRs acted as direct targets of tested microR-
NAs, including ataxia telangiectasia mutated kinase (ATM),
autophagy-like-5 (ATG5), caspase-3, apoptosis-related cysteine
peptidase (CASP3), cyclin-dependent kinase inhibitor 1C
(CDKN1C), cyclin-dependent kinase 1 (CDK1), autophagy-related
10 (ATG10), nuclear factor Ya (NFYA), caspase 2, apoptosis-related
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transfected with indicated microRNA mimics (panel B, miR-429, curve 3, miR-98-5p, curve 4; panel C, miR-297, curve 3, miR-382-3p, curve 4) for 32 h and then exposed to
control medium (CON) or 10 lg/ml cisplatin (CIS) for indicated time. Cell viability characteristics were monitored for the indicated time periods using the MTT assay. Three
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cyclin-dependent kinase inhibitor 2B (CDKN2B). We showed that
tested microRNA mimics inhibited the luciferase activity fused to
the speciﬁc mRNA 30- UTR by 32–56% compared to scrambled
microRNA (Fig. 1B).
We next examined the expression of selected targets in SCC-11
cells exposed to control medium (CON) or 10 lg/ml cisplatin (CIS)
using immunoblotting analysis with subsequent quantiﬁcation of
protein levels normalized for a control b-actin level (Fig. 1C). We
found that the cisplatin exposure of SCC-11 cells led to a substan-
tial up regulation of the following protein: NFYA, CDK2, ATG10,
and CDKN2B, while down regulated ATG5, CDK1, CASP2, and
ATM protein levels (Fig. 1C) supporting the cisplatin effect on
repression or activation of speciﬁc microRNAs subsequently mod-
ulating these protein targets.
3.3. p-DNp63a-Dependent microRNAs modulate the SCC cell response
to cisplatin
Intriguingly, our previous reports showed that SCC-11 cells
were sensitive to cisplatin exposure, while SCC-11M cells become
more resistant to cisplatin-induced cell death [16–18,20]. Simi-
larly, SCC-25 cells were shown to be sensitive, while SCC-25CP ac-
quired resistance to cisplatin treatment [19], probably due to a
greater p-DNp63a/non-p-DNp63a ratio in SCC-25 cells than in
SCC-25CP cells [20].
Since miR-429 or miR-98-5p were down regulated in SCC-11
cells and SCC-25 cells, while miR-297 or miR-383-3p were down
regulated in SCC-11M cells and SCC-25CP cells, we examined the
ability of their mimics to modulate SCC response to cisplatin. All
SCC cells were transfected with the scrambled microRNA and indi-
cated microRNA mimics for 32 h, and were then grown-up without
(CON) or with 10 lg/ml cisplatin (CIS) for 16 h (Fig. 2). Cisplatin
treatment led to a dramatic decline in survival of SCC-11 cells
(4.50-fold, Fig. 2A, curve 2 compared to curve 1), while its effecton SCC-11M cells appeared to be less dramatic (1.66-fold, Fig. 2B,
curve 2 compared to curve 1) suggesting that the altered ability
to phosphorylate DNp63a by ATM kinase in SCC-11M cells renders
them more resistant to cisplatin treatment than SCC-11 cells (by
2.73-fold, Fig. 2B compared to Fig. 2A). Intriguingly, the introduc-
tion of mimics for miR-429 (Fig. 2A, curve 3) or miR-98-5p
(Fig. 2A, curve 4) into SCC-11 cells rendered them to become more
resistant to cisplatin exposure. However, transfection of SCC-11M
cells with mimics for miR-297 or miR-382-3p rendered these resis-
tant cells to become more sensitive to cisplatin treatment (Fig. 2B).
We further found that the transfection of the miR-429 or miR-98-
5p mimics to SCC-25 cells rendered them to becomemore resistant
to cisplatin exposure (Fig. 2C), while miR-297 or miR-382-3p mim-
ics rendered the resistant SCC-25CP cells to become more sensitive
to cisplatin treatment (Fig. 2D).
4. Discussion
In recent years, we found that p-DNp63a is critical for tran-
scriptional regulation of mRNAs and microRNAs leading to activa-
tion or repression of speciﬁc mRNA/microRNA targets [16]. We
deﬁned a number of protein targets encoded by mRNAs or modu-
lated by speciﬁc microRNAs in SCC cells upon cisplatin exposure
[15,16]. Although our previous reports were exclusively related
to the highest cisplatin-induced microRNA changers [16–18], the
remaining microRNAs that were affected by cisplatin exposure
and p-DNp63a eluded our immediate attention.
We found that miR-485-3p, miR-297, miR-382-3p and miR-
194-5p) were up regulated, while miR-98-5p, miR-29c-3p, miR-
101-3p, miR-22-3p, miR-34c-3p, miR-206, miR-429, miR-339-3p,
miR-203a, miR-25-3p, miR-155-5p and miR-148a-3p were down
regulated in cisplatin-sensitive SCC-11 cells compared to more
resistant SCC-11M cells (Fig. 1A and Supplementray Tables SI–SIII).
We then found that the speciﬁc 30-UTR mRNA targets involved in
cell cycle, apoptosis and autophagy were affected by selected
2540 E.A. Ratovitski / FEBS Letters 587 (2013) 2536–2541microRNAs (Fig. 1B), and the following protein targets (e.g. ATM,
NFYA, ATG5 and ATG10, CDKN1C and CDKN2B, CDK1 and CDK2,
and CASP2, and CASP3) were modulated by selected microRNAs
in SCC-11 cells upon cisplatin exposure (Fig. 1C). Notably, this ef-
fect was seen in SCC-11 cells expressing p-DNp63a but not in
SCC-11M cells expressing non-p-DNp63a Fig. 1C). We further
found that similar microRNAs up regulated or down regulated in
SCC cells derived from larynx (SCC-11/SCC-11M) and tongue
(SCC-25/SCC-25CP), while displaying sensitive or resistant pheno-
type to cisplatin therapy (Supplementary Table SIV). Finally, we
have partially modulated the chemoresistance phenotype of both
SCC-11M (larynx) and SCC-25CP (tongue) by the speciﬁc miR-297
or miR-382-3p mimics rendering them more sensitive to cisplatin
treatment (Fig. 2).
We thus determined that the exposure of SCC-11 cells to cis-
platin would lead to modulation of certain proteins involved in cell
cycle arrest, apoptosis, and autophagy (Fig. 3). We predicted that
up regulated microRNAs would decrease the levels of CASP2,
CASP3, and CASP7, PARP8 and PARP11, BMF, CDK1, and CDKN1C),
while down regulated microRNAs would lead to an increase of
CASP2, CASP3 and CASP7, BMF, CDKN1B, CDKN1C and CDKN2B,
APAF1, DFFA, and CDK2 (Fig. 3). We further observed that the
exposure of SCC-11 cells to cisplatin led to a p-DNp63a- depen-
dent modulation of microRNAs potentially implicated in regulation
of autophagic signaling. Although the most of the autophagic pro-
teins appeared to be induced since their corresponding microRNAs
are down regulated in SCC-11 cells upon cisplatin exposure, a few
proteins are likely to be reduced by up regulated microRNAs (miR-
194-5p, miR-297 and miR-630), as reviewed in [7,28]. However, all
protein targets (ATG2B, ATG4A, ATG4C, ATG5, ATG10, ATG12,
ATG16L1, DRAM1, GABARAPL1, MAP1LC3B, SQSTM1 and UVRAG1)
seem to be affected by both down and up regulated microRNAs
(Fig. 3).ATM
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Fig. 3. Schematic representation of the p-DNp63a-dependent protein microRNA-reg
corresponding microRNAs in SCC-11 cells exposed to cisplatin. The microRNAs induced
DNp63a indicated in blue. The corresponding microRNAs are shown next to the speciﬁ
inhibitors of ATM or DNp63a expression suggesting a feedback regulation through micAccumulating evidence supports the idea that microRNA net-
work modulate multiple protein targets involved cell cycles, apop-
tosis and autophagy. For example, miR-449a, -b, and -c are potent
inducers of cell death, or cell cycle arrest, as well as miR-34 regu-
lated by TP53 and E2F1 [21,22]. A few reports showed that CDK
inhibitors could be targets for a microRNA regulation (e.g. miR-
22, miR-296, miR-423 and miR-519 for CDKN1A; miR-221 and
miR-222 for CDKN1A, CDKN1B and CDKN1C), as reviewed else-
where [21,22]. MicroRNAs were also shown to modulate the func-
tion of various pro- and anti- apoptotic proteins [23]. miR-885-3p
was shown to decrease CASP3 levels [17], while miR-15a, miR-16,
and miR-153 reduce BCL2 expression [24,25].
Emerging evidence shows that the speciﬁc microRNAs are in-
volved in the regulation of autophagy and play a role in modulating
the cross talk between autophagy and apoptosis contributing to
cancer and tumor cell response to chemotherapy [7,26]. Numerous
microRNAs were shown to engage in modulation of autophagic
pathway (e.g. miR-30a, miR-376b and miR-519a-3p for ATG6/
BECN1; miR-101a for ATG4D; miR-17, -20, -93a and -106 for
SQSTM1; miR-204 for MAP1LC3; miR-885-3p for ULK2; miR-101
for RAB5A; miR-630 and miR-374a-5p for UVRAG; miR-30a, miR-
181a-5p and miR-374a-5p for ATG5; miR-630 for ATG12; miR-
376b for ATG4; miR-375 for ATG7; miR-519a-3p for ATG10 and
ATG16; miR-885-3p for ATG16; miR-101a for ATG4 and RAB5A;
miR-34a for ATG9; and miR-130a for ATG2), as reviewed in [7,26].
By modulating BECN1 or ATG4-ATG8 conjunction, miR-30a or
miR-101a-3p lead to the suppression of autophagic phenotype in
cancer cells, thereby contributing to cancer progression [27,28].
SQSTM1 (p62), as a signaling hub, was identiﬁed as a key target
for multiple microRNAs, whose elimination through microRNA
modulation may potentially inhibit the proliferation of these tu-
mor cells [29]. Enforced expression of Atg5 renders tumor cells sen-
sitive to chemotherapy, whereas silencing the Atg5 resulted in18a-5p, 181a-5p, 
194-5p, 203a, 297,
374a-5p, 519a-3p, 
603
181a-5p
374a-5p
519a-3p
603
-P
CASP7194-5p
18a-5p
CASP3885-3p
98-5p
7-5p
PARP11185-5p
CASP2185-5p
519a-3p
429
BMF
760
34c-3p
29c-3p
PARP8485-5p
DFFA485-5p
214-3p
APAF1115-5p
DKN2B
429
CDK2
29c-3p
429
CDK1
382-3p
ulated targets involved in autophagy, cell cycle arrest and apoptosis and their
by cisplatin/p-DNp63a indicated in red, while microRNAs repressed by cisplatin/p-
c protein target. MicroRNAs listed on right next to ATM or DNp63a are potential
roRNA-dependent mechanism [31].
E.A. Ratovitski / FEBS Letters 587 (2013) 2536–2541 2541partial resistance to anticancer drugs, thereby reinforcing new ven-
ues in clinical anticancer therapies [30].
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